PFS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fei Li, Keshu Zhou, Wei Xu, Guohui Cui, Shuhua Yi, Jie Jin, Zunmin Zhu, Aili He, Jianqing Mi, Zhongjun Xia, Xiaobing Huang, Xin Zhou, Wenzheng Yu, Jingming Guo, Qingshu Zeng, Shihua Huang, Yuerong Shuang, Hongling Peng, Lihua Qiu, Bing Xu, Yan Li, Yanli Yang, Fuling Zhou, Yafei Wang, Lihong Liu, Jinhai Ren, Ying Li, Wei Yang, Jian Gu, Guifang Ouyang, Luoming Hua, Jin Zhang, Qing Xiao, Shunqing Wang, Qingyuan Zhang, Jing Liu, Kaiyang Ding, Liansheng Zhang, Yun Zeng, Zhenyu Li, Qin Wen, Kaibo Gao, Haiping Yang, Yirong Jiang, Yijian Chen, Zengjun Li, Xinran Tang, Weige Wang, Renbin Zhao, Lugui Qiu, Jianyong Li
Signal Transduct Target Ther 11(1) 261
Orelabrutinib is a potent, irreversible, and highly-selective BTK inhibitor that has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). This randomized, phase 3 study (ClinicalTrials.gov identifier: NCT04578613) compared orelabrutinib with chemoimmunotherapy in patients with treatment-naïve CLL/SLL. From February 20, 2021, to July 8, 2024, 192 eligible patients were randomly assigned (1:1) to receive either orelabrutinib (91 patients) or chlorambucil plus rituximab (101 patients), comprising the intention-to-treat population. At a median follow-up of 21.4 months (data cutoff, May 17, 2024), the primary endpoint of progression-free survival (PFS) per independent review committee (IRC) was not reached (NR; 95% CI, not estimable [NE]-NE) with orelabrutinib versus 19.4 months (95% CI, 16.6-NE) with chlorambucil plus rituximab (hazard ratio [HR], 0.32; 95% CI, 0.18-0.58; p < 0.0001; crossing the efficacy boundary). The IRC-assessed overall response rate (90.1% vs 79.2%; p = 0.041) and duration of response (HR, 0.30; 95% CI, 0.15-0.60; p = 0.0003) also favored orelabrutinib over chlorambucil plus rituximab. In the safety population, treatment-related adverse events occurred in 82 of 91 patients (90.1%) receiving orelabrutinib and 89 of 98 patients (90.8%) receiving chlorambucil plus rituximab, with 32 (35.2%) and 59 (60.2%) at grade 3 or worse, respectively. Orelabrutinib maintained or improved patient-reported outcomes compared with chemoimmunotherapy. In summary, orelabrutinib significantly improved PFS and response versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL, with a manageable safety profile, supporting it as an effective alternative first-line option.
2 个 Figure · 3 个 KM 面板
Fig. 2 Progressive-free survival as assessed by the independent review committee in the intention–to–treat population. a Kaplan-Meier curve for progressive-free survival. b Analyses of progression-free survival in key subgroups. The tick marks indicate censored data. Between-group difference was evaluated with the log-rank test. P values were two-sided. The Cox proportional-hazards model was used to assess the HRs and associated 95% CIs. PFS progressive-free survival, mo months, NR not reached, NE not estimable, HR hazard ratios, CI confidence interval
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 IRC-assessed DoR and overall survival in the intention–to–treat population. a Kaplan-Meier curve for IRC-assessed DoR. b Kaplan-Meier curves for overall survival. The tick marks indicate censored data. Between-group difference was evaluated with the log-rank test. P values were two-sided. The Cox proportional-hazards model was used to assess the HRs and associated 95% CIs. DoR duration of response, OS overall survival, mo months, NR not reached, NE not estimable, HR hazard ratios, CI confidence interval
这些图片未产生 KM 曲线结果,不在主页面重复展示。